About Relay Therapeutics, Inc.
https://www.relaytx.comRelay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.
CEO
Sanjiv K. Patel MBBS
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 126
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Raymond James
Strong Buy
HC Wainwright & Co.
Buy
Guggenheim
Buy
Goldman Sachs
Buy
Stifel
Buy
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
SB INVESTMENT ADVISERS (UK) LTD
Shares:27.9M
Value:$225.19M
COMMODORE CAPITAL LP
Shares:17M
Value:$137.19M
POINT72 ASSET MANAGEMENT, L.P.
Shares:14.77M
Value:$119.22M
Summary
Showing Top 3 of 219
About Relay Therapeutics, Inc.
https://www.relaytx.comRelay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 ▼ | $79.64M ▲ | $-74.15M ▼ | 0% ▲ | $-0.43 ▼ | $-73.4M ▲ |
| Q2-2025 | $677K ▼ | $77.52M ▼ | $-70.38M ▲ | -10.4K% ▼ | $-0.41 ▲ | $-75.84M ▲ |
| Q1-2025 | $7.68M ▲ | $92.55M ▲ | $-77.06M ▼ | -1K% ▼ | $-0.46 ▼ | $-83.66M ▼ |
| Q4-2024 | $0 | $84.98M ▼ | $-76M ▲ | 0% | $-0.45 ▲ | $-83.64M ▲ |
| Q3-2024 | $0 | $96.37M | $-88.11M | 0% | $-0.63 | $-95M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $596.43M ▼ | $670M ▼ | $62.29M ▼ | $607.71M ▼ |
| Q2-2025 | $656.77M ▼ | $728.84M ▼ | $63.18M ▼ | $665.66M ▼ |
| Q1-2025 | $710.36M ▼ | $799.36M ▼ | $78.28M ▼ | $721.08M ▼ |
| Q4-2024 | $781.32M ▼ | $871.3M ▼ | $93.5M ▲ | $777.79M ▼ |
| Q3-2024 | $839.61M | $930.12M | $91.25M | $838.86M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-74.15M ▼ | $-62.12M ▼ | $39.73M ▼ | $17K ▼ | $-22.38M ▼ | $-62.12M ▼ |
| Q2-2025 | $-70.38M ▲ | $-55.26M ▲ | $75.15M ▲ | $653K ▲ | $20.54M ▲ | $-55.29M ▲ |
| Q1-2025 | $-77.06M ▼ | $-73.21M ▼ | $42.47M ▲ | $0 ▼ | $-30.75M ▼ | $-73.59M ▼ |
| Q4-2024 | $-76M ▲ | $-57.87M ▲ | $29M ▲ | $800K ▼ | $-28.07M ▼ | $-57.87M ▲ |
| Q3-2024 | $-88.11M | $-75.08M | $-126.16M | $218.89M | $17.64M | $-75.31M |
CEO
Sanjiv K. Patel MBBS
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 126
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Raymond James
Strong Buy
HC Wainwright & Co.
Buy
Guggenheim
Buy
Goldman Sachs
Buy
Stifel
Buy
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
SB INVESTMENT ADVISERS (UK) LTD
Shares:27.9M
Value:$225.19M
COMMODORE CAPITAL LP
Shares:17M
Value:$137.19M
POINT72 ASSET MANAGEMENT, L.P.
Shares:14.77M
Value:$119.22M
Summary
Showing Top 3 of 219